NNZ 2591
| Catalog Number | Pack Size | List Price* | Promo Price* | Quantity | |
|---|---|---|---|---|---|
| HY-148195-1MG | 1 mg | 248,00 | 161,20 | Add | |
| HY-148195-5MG | 5 mg | 552,00 | 358,80 | Add | |
| HY-148195-10MG | 10 mg | 875,00 | 568,80 | Add | |
| HY-148195-25MG | 25 mg | 1'737,00 | 1'129,10 | Add | |
| HY-148195-50MG | 50 mg | 2'774,00 | 1'803,10 | Add | |
| HY-148195-100MG | 100 mg | 4'430,00 | 2'879,50 | Add |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Promotion runs until 31.12.2024Year-End Promotion : 35% discount on the entire MedChem Express portfolio
NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome[1][2][3].
| Category | Peptide |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Neurological Disease |
| Format | Solubility: DMSO : 18.75 mg/mL (ultrasonic) |
| Grade | Clinical information: No Development Reported |
| Purity | 99.98% |
| Molecular Formula | C10H14N2O2 |
| Molecular Weight | 194.23 |
| CAS-Number | 847952-38-9 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
